| scholarly article | Q13442814 |
| P50 | author | Alex Sparreboom | Q71780219 |
| P2093 | author name string | Gary H Lyman | |
| P2860 | cites work | Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens | Q80495856 |
| Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy | Q80809590 | ||
| Undertreatment of obese women receiving breast cancer chemotherapy | Q81850669 | ||
| Effect of obesity on prognosis after early-stage breast cancer | Q82657718 | ||
| Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice | Q83309707 | ||
| Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy | Q83357792 | ||
| Comparative effectiveness research in oncology: the need for clarity, transparency and vision | Q84131450 | ||
| Comparative effectiveness research in oncology: an overview | Q85199223 | ||
| Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study | Q24684767 | ||
| Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults | Q28131763 | ||
| Advances in chemotherapy of cancer in man | Q28213539 | ||
| Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute | Q28275506 | ||
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| The obesity epidemic in the United States--gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis | Q29615800 | ||
| Dose translation from animal to human studies revisited | Q29618049 | ||
| Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure | Q33182389 | ||
| Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel | Q33185690 | ||
| Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? | Q33296440 | ||
| Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese | Q33303164 | ||
| Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2. | Q33384061 | ||
| Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy | Q33385774 | ||
| Description of Current Practices of Empiric Chemotherapy Dose Adjustment in Obese Adult Patients | Q33846184 | ||
| Commentary: chemotherapy dosing in obese patients with cancer-the need for evidence-based clinical practice guidelines | Q34459673 | ||
| 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline | Q34523108 | ||
| The use of body surface area as a criterion of drug dosage in cancer chemotherapy. | Q34538988 | ||
| Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. | Q34547428 | ||
| Impact of chemotherapy dose intensity on cancer patient outcomes | Q34603745 | ||
| Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline | Q34637194 | ||
| Breast cancer adjuvant chemotherapy dosing in obese patients: dissemination of information from clinical trials to clinical practice | Q34659874 | ||
| Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults | Q34662040 | ||
| A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate | Q34702164 | ||
| Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). | Q34856664 | ||
| Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials | Q35740423 | ||
| Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients | Q35783532 | ||
| Race/ethnic issues in obesity and obesity-related comorbidities | Q35794454 | ||
| What is the best size descriptor to use for pharmacokinetic studies in the obese? | Q35826324 | ||
| Weight-based chemotherapy dosing in obese patients with cancer: back to the future | Q36095287 | ||
| Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity | Q36100858 | ||
| Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. | Q36243741 | ||
| Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents | Q36287956 | ||
| Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials | Q37051591 | ||
| Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. | Q37125053 | ||
| Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy | Q37161846 | ||
| Simplified calculation of body-surface area. | Q55060911 | ||
| Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy | Q56786457 | ||
| Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu | Q57578575 | ||
| Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis | Q68803988 | ||
| Kinetics of mammary tumor cell growth and implications for therapy | Q70622373 | ||
| The use of tumor growth kinetics in planning "curative" chemotherapy of advanced solid tumors | Q71285664 | ||
| Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541 | Q71778665 | ||
| Dose: a critical factor in cancer chemotherapy | Q72154949 | ||
| Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up | Q72596355 | ||
| Experimental studies with actinomycin D | Q74735609 | ||
| Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B | Q77156165 | ||
| The impact of obesity and disease on busulfan oral clearance in adults | Q77850474 | ||
| Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer | Q79433843 | ||
| Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey | Q37477083 | ||
| Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. | Q37598847 | ||
| Effect of obesity on the pharmacokinetics of drugs in humans | Q37672600 | ||
| Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review | Q37729615 | ||
| Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis | Q37767169 | ||
| Obesity and ovarian cancer survival: a systematic review and meta-analysis | Q38011565 | ||
| Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults | Q38019839 | ||
| Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review | Q38037349 | ||
| Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma.A southwest oncology group study | Q38537741 | ||
| Influence of obesity on drug disposition | Q39678481 | ||
| Health and economic burden of the projected obesity trends in the USA and the UK. | Q39713652 | ||
| Growth Curve of an Experimental Solid Tumor Following Radiotherapy | Q40074202 | ||
| The importance of dose intensity in chemotherapy of metastatic breast cancer | Q40190080 | ||
| Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice | Q40425420 | ||
| Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma | Q40701794 | ||
| Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer | Q40784950 | ||
| Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations | Q40789215 | ||
| Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative | Q41123160 | ||
| Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer | Q41450904 | ||
| Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. | Q43087932 | ||
| Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy | Q43445329 | ||
| Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area | Q43587855 | ||
| Abdominal obesity and breast cancer risk | Q43621385 | ||
| Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer | Q43685297 | ||
| Neutropenia-wise and pound-foolish: safe and effective chemotherapy in massively obese patients | Q43878612 | ||
| Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin | Q44119521 | ||
| Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma | Q44524741 | ||
| Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices | Q44691615 | ||
| Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. | Q44765697 | ||
| Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. | Q44776010 | ||
| Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. | Q44796944 | ||
| REACH 2010 Surveillance for Health Status in Minority Communities --- United States, 2001--2002. | Q45023903 | ||
| Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study | Q45069647 | ||
| Tumor size, sensitivity to therapy, and design of treatment schedules | Q45287063 | ||
| Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial | Q46443839 | ||
| Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial | Q46755320 | ||
| Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. | Q46938259 | ||
| Influence of lean body weight on anticancer drug clearance | Q47246112 | ||
| Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis | Q47311801 | ||
| Association between obesity at diagnosis and weight change during induction and survival in pediatric acute lymphoblastic leukemia | Q47323369 | ||
| Estimation of human body surface area from height and weight | Q47387886 | ||
| Is dose normalization to weight or body surface area useful in adults? | Q47449894 | ||
| Racial Disparity in the Dose and Dose Intensity of Breast Cancer Adjuvant Chemotherapy | Q47580264 | ||
| Factors affecting cytochrome P-450 3A activity in cancer patients. | Q47873497 | ||
| Obesity and therapy-related toxicity in patients treated for small-cell lung cancer | Q50114051 | ||
| Dosing in obesity: a simple solution to a big problem. | Q50660420 | ||
| Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae. | Q50865817 | ||
| The genetic origin of drug resistance in neoplasms: implications for systemic therapy. | Q52688528 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| obesity | Q12174 | ||
| P304 | page(s) | 451-459 | |
| P577 | publication date | 2013-07-16 | |
| P1433 | published in | Nature Reviews Clinical Oncology | Q641640 |
| P1476 | title | Chemotherapy dosing in overweight and obese patients with cancer | |
| P478 | volume | 10 |
| Q53592464 | A time to stop, a time to start: high-dose chemotherapy in overweight and obese patients. |
| Q50185850 | Adipose tissue: The dysfunctional adipocyte - a cancer cell's best friend. |
| Q43544522 | Appropriate chemotherapy dosing in obese patients with cancer |
| Q28545175 | Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective review |
| Q53062804 | Body Mass Index and Locoregional Recurrence in Women with Early-Stage Breast Cancer. |
| Q60959855 | Chemoresistance: Intricate Interplay Between Breast Tumor Cells and Adipocytes in the Tumor Microenvironment |
| Q37706371 | Chemotherapy can induce weight normalization of morbidly obese mice despite undiminished ingestion of high fat diet |
| Q98154697 | Chemotherapy dosing and toxicity in a patient with muscular dystrophy |
| Q47803255 | Chemotherapy-induced neutropenia and the prognosis of colorectal cancer: a meta-analysis of cohort studies |
| Q40523171 | Comparison of two different formulas for body surface area in adults at extremes of height and weight |
| Q88599453 | Development of a simplified multivariable model to predict neutropenic complications in cancer patients undergoing chemotherapy |
| Q33573539 | Effect of age and body weight on toxicity and survival in pediatric acute myeloid leukemia: results from NOPHO-AML 2004. |
| Q36053032 | Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index |
| Q48179867 | Impact of Pretreatment Neutrophil Count on Chemotherapy Administration and Toxicity in Dogs with Lymphoma Treated with CHOP Chemotherapy |
| Q41176272 | Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy |
| Q35748477 | Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies |
| Q35606589 | Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance |
| Q26775949 | Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer |
| Q38522993 | Modifiable Lifestyle Factors and Breast Cancer Outcomes: Current Controversies and Research Recommendations |
| Q30361298 | Obesity and cancer pathogenesis. |
| Q91000127 | Obesity and cancer treatment efficacy: Existing challenges and opportunities |
| Q26786829 | Obesity and cancer: mechanistic insights from transdisciplinary studies |
| Q61799036 | Obesity, Leptin and Breast Cancer: Epidemiological Evidence and Proposed Mechanisms |
| Q39205170 | Obesity-associated digestive cancers: A review of mechanisms and interventions |
| Q87139554 | Obesity-associated gastrointestinal tract cancer: from beginning to end |
| Q48201308 | Physical activity, obesity and survival in diffuse large B-cell and follicular lymphoma cases |
| Q86486463 | Sarcopenia and chemotherapy dosing in obese patients |
| Q37572738 | Sarcopenia and chemotherapy-mediated toxicity |
| Q52324116 | The Impact of Obesity on Breast Cancer. |
| Q38261878 | The challenge of obesity in paediatric leukaemia treatment: it is not just size that matters |
| Q51101109 | To cap or not to cap: chemotherapy dosing in obese adult hematology patients. |
| Q37480946 | Weight control interventions improve therapeutic efficacy of dacarbazine in melanoma by reversing obesity-induced drug resistance |
| Q26797301 | Why does obesity promote cancer? Epidemiology, biology, and open questions |
Search more.